Concepedia
Statistics
Publications
3
Citations
41
H-Index
Active since
2022
Affiliations
Dana-Farber Cancer Institute(Current)
AstraZeneca (Spain)
Seoul National University Hospital
Université Paris-Saclay
Taichung Veterans General Hospital
P.A. Jänne is an author at Dana-Farber Cancer Institute specializing in oncology, molecular oncology, and egfr inhibition.
Publications per year
2022–2025
MA12.03 FLAURA2: Resistance, and Impact of Baseline TP53 Alterations in Patients Treated With 1L Osimertinib ± Platinum-Pemetrexed
J.C. Yang, Jacqulyne Robichaux, D. Planchard et al. · Journal of Thoracic Oncology · 2024 · 21 citations · Full text
Medicine, Oncology, Pharmacology +17
987P Sunvozertinib for NSCLC patients with EGFR exon 20 insertion mutations: Preliminary analysis of WU-KONG6, the first pivotal study
Meng Wang, J.C-H. Yang, P. Mitchell et al. · Annals of Oncology · 2022 · 10 citations · Full text
Medicine, Molecular Genetics, Oncology +9
PL02.06 First-Line Osimertinib + Chemotherapy Versus Osimertinib Monotherapy in EGFRm Advanced NSCLC: FLAURA2 Final Overall Survival
D. Planchard, P.A. Jänne, K. Kobayashi et al. · Journal of Thoracic Oncology · 2025 · 10 citations
Medicine, Oncology, Pharmacology +8
1–3 of 3